CHARLOTTE, N.C., June 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from an integrated dataset of two phase 3 studies, Study 301 and Study 302, which showed that patients treated with Northera™ (droxidopa) experienced improvements in their symptoms of Neurogenic Orthostatic Hypotension (also known as NOH or Neurogenic OH) as measured by the Orthostatic Hypotension Questionnaire (OHQ) composite score (p=0.001) and a number of individual symptoms, including dizziness (p=0.004). The results, which include data from over 250 patients with symptomatic Neurogenic OH and diagnoses of Parkinson’s disease, multiple system atrophy (MSA), pure autonomic failure (PAF), dopamine beta hydroxylase deficiency or nondiabetic autonomic neuropathy, were presented by Christopher Mathias, MD at the 16th International Congress of Parkinson’s Disease and Movement Disorders in Dublin, Ireland today (Integrated Efficacy Analysis of Droxidopa in 2 Double-Blind, Placebo-Controlled Phase 3 Studies in Patients with Neurogenic Orthostatic Hypotension, Abstract/Poster #1296).
